Trial Profile

A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma (FLORA-5)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oregovomab (Primary) ; Carboplatin; Paclitaxel
Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Registrational; Therapeutic Use
Acronyms FLORA-5
Sponsors CanariaBio; OncoQuest

09 Jul 2025 Planned End Date changed from 26 Aug 2027 to 26 Aug 2028.
09 Jul 2025 Planned primary completion date changed from 26 Sep 2025 to 26 Mar 2026.
23 Jan 2024 According to a Quest PharmaTech Inc. media release, DSMB expressed, there is a possibility of significant efficacy in overall survival and recommended that follow up observations be continued in study subjects.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com